Enomoto D, Yamamoto K, Matsumoto Y, Morioka A, et al. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma. Anticancer Res 2023;43:1317-1323.
PMID: 36854508